サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1555475

抗真菌薬市場：薬剤クラス別、適応症別、投与経路別、感染タイプ別、流通チャネル別、国別、地域別 - 産業分析、市場規模、市場シェア、2024年～2032年の予測

Antifungal Drugs Market, By Drug Class, By Indication, By Route of Administration, By Infection Type, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 388 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
抗真菌薬市場：薬剤クラス別、適応症別、投与経路別、感染タイプ別、流通チャネル別、国別、地域別 - 産業分析、市場規模、市場シェア、2024年～2032年の予測
出版日: 2024年08月20日
発行: AnalystView Market Insights
ページ情報: 英文 388 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

抗真菌薬の市場規模は2023年に156億7,823万米ドルとなり、2024年から2032年にかけてCAGR3.79％で拡大

抗真菌薬市場 - 市場力学

真菌感染症の蔓延が市場成長を牽引すると予測

カンジダ症、アスペルギルス症、クリプトコッカス症などの真菌感染症は、特にHIV/AIDS患者、がん患者、臓器移植を受けた患者など、免疫力が低下している人の間でますます流行しています。このような感染症の頻度の増加は、認知度の向上や診断ツールの利用可能性と共に、効果的な抗真菌療法に対する需要を牽引しています。米国疾病予防管理センターによると、真菌症による入院患者数は年間75,000人以上、外来患者数は900万人近くにのぼります。また、新薬クラスや革新的な製剤の開発など、抗真菌治療の研究開発が進んでいることも、大きな市場機会をもたらしています。とはいえ、治療費の高さが市場拡大の課題となる可能性もあります。

抗真菌薬市場 - 主要洞察

弊社のリサーチアナリストの分析によると、世界市場は予測期間（2024年～2032年）に約3.79%のCAGRで年間成長すると推定されます。

薬剤クラス別では、アゾール系薬剤が2023年に最大の市場シェアを示すと予測されます。

適応症別では、2023年にはカンジダ症が主要タイプでした。

投与経路別では、2023年に経口剤が主要タイプでした。

感染タイプ別では、2023年には全身性抗真菌感染症が主要タイプでした。

流通チャネル別では、2023年に病院薬局が主要タイプでした。

地域別では、北米が2023年の売上高でトップでした。

抗真菌薬市場 - セグメンテーション分析：

世界の抗真菌薬市場は薬剤クラス別、適応症別、投与経路別、感染タイプ別、流通チャネル別、地域別に区分されます。

市場は薬剤クラス別に3つに分類されます：アゾール系、エキノカンディン系、ポリエン系、アリルアミン系、その他です。アゾール系抗真菌薬は市場で圧倒的な地位を占めています。このクラスの抗真菌薬は、多くの真菌感染症の治療に広く利用されています。その作用機序には、真菌細胞膜の重要な要素であるエルゴステロール合成の阻害が含まれ、その結果、最終的に真菌は死滅します。

市場は適応症によって3つのカテゴリーに分類されます：皮膚糸状菌症、アスペルギルス症、カンジダ症、その他です。カンジダ症は市場で優位な地位を占めています。カンジダ種に起因するこの疾患は、表在性と全身性の侵襲性の両形態で現れる可能性のある、蔓延性の真菌感染症です。カンジダ症に対する抗真菌薬の選択は、感染の重症度や部位、免疫状態や過去の治療など患者固有の要因に影響されます。

市場は投与経路によって3つのセグメントに分類されます：経口剤、局所剤、注射剤です。市場をリードするのは経口剤です。経口抗真菌薬は、口腔内の真菌感染症（口腔カンジダ症や鵞口瘡と呼ばれることが多い）に対処するために使用されます。

市場は感染タイプによって2つのセグメントに分類されます：全身性抗真菌感染症と表在性抗真菌感染症です。全身性抗真菌性感染症は市場で優位を占めています。全身性抗真菌感染症の治療は、重症の真菌感染症に対処するために極めて重要であり、特定の真菌病原体と患者の状態に基づいて適切な抗真菌剤を選択する必要があります。

市場は流通チャネルによって2つのセグメントに分類されます：病院薬局、小売薬局、その他です。病院薬局は市場で支配的な地位を占めています。病院薬局は医薬品の選択、調製、投与を担当し、効果的かつ安全な治療を実現しています。

抗真菌薬市場 - 地理的洞察

抗真菌薬市場は、北米、ラテンアメリカ、欧州、アジア太平洋、中東・アフリカを含む広範な地域にまたがっています。これらの地域は、事業活動に貢献している国々に基づいてさらに分類されます。北米が市場をリードしているのは、その先進的なヘルスケア・インフラと質の高い医療施設に起因しています。特に米国は、最先端の病院、研究機関、診断センターを備えた高度に発達したヘルスケアシステムを特徴としています。感染症専門センターを含む高度医療施設の存在は、真菌感染症の迅速かつ正確な診断を容易にしています。最近のデータや報告によると、米国の2021年の総医療費は4兆3,000億米ドルに達し、国内総生産（GDP）の18.5％を占めると予測されています。欧州は、政府部門と民間部門の両方からの投資増加により、市場成長において第2位の地域となっています。

抗真菌薬市場 - 競合情勢：

抗真菌薬市場の競合情勢は、薬剤の有効性、安全性プロファイル、製剤の進歩、価格戦略など様々な要因の影響を受けています。各社は新規抗真菌化合物の発見、現行製剤の改良、薬剤耐性に関する問題への対処を目的とした研究開発に多大なリソースを割いています。主な競合要素としては、ドラッグデリバリーシステムの革新、併用療法、新クラスの抗真菌剤の導入などが挙げられます。企業は、特に真菌感染症が大きな課題となっている新興市場において、地理的プレゼンスの拡大に努めています。市場でのプレゼンスを確立するための一般的な戦略としては、戦略的パートナーシップの形成、買収の追求、現地製造への参入などが挙げられます。耐性株に対する治療法の開拓や新たな治療オプションの提供に注力する企業は、市場においてより強固な地位を獲得する可能性が高いです。

目次

第1章 抗真菌薬市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 抗真菌薬の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 抗真菌薬産業の調査

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 抗真菌薬市場：COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19以後の影響分析

第6章 抗真菌薬市場情勢

  • 抗真菌薬市場シェア分析、2023年
  • 内訳データ：主要メーカー別
    • 既存企業の分析
    • 新興企業の分析

第7章 抗真菌薬市場 - 薬剤クラス別

  • 概要
    • セグメントシェア分析：薬剤クラス別
    • アゾール
    • エキノキャンディン
    • ポリエン
    • アリルアミン
    • その他

第8章 抗真菌薬市場 - 適応症別

  • 概要
    • セグメントシェア分析：適応症別
    • 皮膚糸状菌症
    • アスペルギルス症
    • カンジダ症
    • その他

第9章 抗真菌薬市場 - 投与経路別

  • 概要
    • セグメントシェア分析：投与経路別
    • 経口
    • 局所
    • 注射剤

第10章 抗真菌薬市場 - 感染症タイプ別

  • 概要
    • セグメントシェア分析：感染症別
    • 全身性抗真菌感染症
    • 表面抗真菌感染症

第11章 抗真菌薬市場 - 流通チャネル別

  • 概要
    • セグメントシェア分析：流通チャネル別
    • 病院薬局
    • 小売薬局
    • その他

第12章 抗真菌薬市場 - 地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第13章 主要ベンダー分析 - 抗真菌薬業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Novartis AG
    • Pfizer, Inc.
    • Bayer AG
    • Sanofi
    • Merck &Co., Inc.
    • GlaxoSmithKline plc
    • Abbott
    • Glenmark
    • Enzon Pharmaceuticals, Inc.
    • Astellas Pharma, Inc.
    • その他

第14章 アナリストの全方位展望

目次
Product Code: ANV3627

REPORT HIGHLIGHT

Antifungal Drugs Market size was valued at USD 15,678.23 Million in 2023, expanding at a CAGR of 3.79% from 2024 to 2032.

Antifungal medications are utilized to address fungal infections. Fungi present in the soil, air, and on the skin can result in conditions such as yeast infections, ringworm, and infections affecting the nails and skin. Inhalation of fungal spores may result in respiratory ailments. Individuals with compromised immune systems are at a higher risk for fungal infections that necessitate antifungal treatment. A range of antifungal drugs is available to combat these infections, with some being accessible over the counter while others require a prescription, contingent upon the specific medication.

Antifungal Drugs Market- Market Dynamics

The growing prevalence of fungal infections is anticipated to drive the growth of the market

Fungal infections, including candidiasis, aspergillosis, and cryptococcosis, are increasingly prevalent, especially among individuals with compromised immune systems, such as those suffering from HIV/AIDS, cancer, or those who have undergone organ transplants. The rising frequency of these infections, along with enhanced awareness and the availability of diagnostic tools, is driving the demand for effective antifungal therapies. According to the Centers for Disease Control and Prevention, over 75,000 hospitalizations and nearly 9 million outpatient visits for fungal diseases occur annually. Additionally, ongoing research and development in antifungal treatments, which includes the identification of new drug classes and innovative formulations, present substantial market opportunities. Nevertheless, the high cost of treatment may pose a challenge to market expansion.

Antifungal Drugs Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 3.79% over the forecast period (2024-2032)

Based on Drug Class segmentation, Azoles was predicted to show maximum market share in the year 2023

Based on Indication segmentation, Candidiasis was the leading type in 2023

Based on Route of Administration segmentation, Oral was the leading type in 2023

Based on Infection Type segmentation, Systemic antifungal infections were the leading type in 2023

Based on Distribution Channel segmentation, Hospital pharmacies were the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Antifungal Drugs Market- Segmentation Analysis:

The Global Antifungal Drugs Market is segmented based on Drug Class, Indication, Route of Administration, Infection Type, Distribution Channel, and Region.

The market is segmented into three categories according to Drug Class: Azoles, Echinocandins, Polyenes, Allylamines, and Others. Azoles hold a dominant position in the market. This class of antifungal medications is widely utilized for the treatment of numerous fungal infections. Their mechanism of action involves the inhibition of ergosterol synthesis, a crucial element of fungal cell membranes, resulting in the eventual demise of the fungus.

The market is segmented into three categories according to Indication: Dermatophytosis, Aspergillosis, Candidiasis, and Others. Candidiasis holds a predominant position in the market. This condition, resulting from Candida species, represents a prevalent fungal infection that can manifest in both superficial and systemic, invasive forms. The selection of antifungal medications for candidiasis is influenced by the severity and location of the infection, as well as patient-specific factors, including immune status and previous treatments.

The market is classified into three segments according to Route of administration: Oral, Topical, and Injectable. The Oral segment leads the market. Oral antifungal medications are utilized to address fungal infections within the oral cavity, frequently referred to as oral candidiasis or thrush.

The market is categorized into two segments according to Infection Type: Systemic antifungal infections and superficial antifungal infections. Systemic antifungal infections hold a predominant position in the market. The treatment of systemic antifungal infections is crucial for addressing severe fungal infections and requires the selection of a suitable antifungal agent based on the specific fungal pathogen and the patient's condition.

The market is categorized into two segments based on Distribution Channels: Hospital pharmacies, Retail pharmacies, and others. Hospital pharmacies hold a dominant position in the market. They are tasked with the selection, preparation, and administration of medications, thereby ensuring both effective and safe treatment.

Antifungal Drugs Market- Geographical Insights

This market is geographically extensive, encompassing North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These areas are further categorized based on the countries contributing to business activities. North America leads the market, attributed to its advanced healthcare infrastructure and high-quality medical facilities. The United States, in particular, features a highly developed healthcare system, equipped with cutting-edge hospitals, research institutions, and diagnostic centers. The presence of advanced medical facilities, including specialized centers for infectious diseases, facilitates prompt and precise diagnosis of fungal infections. Recent data and reports indicate that total healthcare expenditure in the United States for 2021 is projected to reach USD 4.3 trillion, representing 18.5% of the nation's GDP. Europe ranks as the second-largest region for market growth, driven by increased investments from both government and private sectors.

Antifungal Drugs Market- Competitive Landscape:

The competitive landscape of the antifungal drugs market is influenced by various factors, including the effectiveness of medications, safety profiles, advancements in formulations, and pricing strategies. Organizations allocate substantial resources to research and development aimed at discovering novel antifungal compounds, enhancing current formulations, and tackling issues related to drug resistance. Key competitive elements include innovations in drug delivery systems, combination therapies, and the introduction of new classes of antifungal agents. Companies strive to broaden their geographical presence, particularly in emerging markets where fungal infections pose a significant challenge. Common strategies for establishing a market presence include forming strategic partnerships, pursuing acquisitions, and engaging in local manufacturing. Firms that concentrate on developing treatments for resistant strains or providing new therapeutic options are likely to achieve a stronger position in the market.

Recent Developments:

In August 2023, Sandoz, a prominent global entity in the field of generic and biosimilar pharmaceuticals, announced the successful acquisition of the global brand rights for the renowned systemic antifungal medication Mycamine (micafungin sodium, known as Funguard in Japan) from Astellas.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ANTIFUNGAL DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Novartis AG
  • Pfizer, Inc.
  • Bayer AG
  • Sanofi
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Abbott
  • Glenmark
  • Enzon Pharmaceuticals, Inc.
  • Astellas Pharma, Inc.
  • Others

GLOBAL ANTIFUNGAL DRUGS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Azoles
  • Echinocandins
  • Polyenes
  • Allylamines
  • Others

GLOBAL ANTIFUNGAL DRUGS MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Dermatophytosis
  • Aspergillosis
  • Candidiasis
  • Others

GLOBAL ANTIFUNGAL DRUGS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Topical
  • Injectable

GLOBAL ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE- MARKET ANALYSIS, 2019 - 2032

  • Systemic antifungal infections
  • Superficial antifungal infections

GLOBAL ANTIFUNGAL DRUGS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital pharmacies
  • Retail pharmacies
  • Others

GLOBAL ANTIFUNGAL DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Antifungal Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Antifungal Drugs Market Snippet by Drug Class
    • 2.1.2. Antifungal Drugs Market Snippet by Indication
    • 2.1.3. Antifungal Drugs Market Snippet by Route of Administration
    • 2.1.4. Antifungal Drugs Market Snippet by Infection Type
    • 2.1.5. Antifungal Drugs Market Snippet by Distribution Channel
    • 2.1.6. Antifungal Drugs Market Snippet by Country
    • 2.1.7. Antifungal Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Antifungal Drugs Key Market Trends

  • 3.1. Antifungal Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Antifungal Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Antifungal Drugs Market Opportunities
  • 3.4. Antifungal Drugs Market Future Trends

4. Antifungal Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Antifungal Drugs Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Antifungal Drugs Market Landscape

  • 6.1. Antifungal Drugs Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Antifungal Drugs Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 7.1.2. Azoles
    • 7.1.3. Echinocandins
    • 7.1.4. Polyenes
    • 7.1.5. Allylamines
    • 7.1.6. Others

8. Antifungal Drugs Market - By Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 8.1.2. Dermatophytosis
    • 8.1.3. Aspergillosis
    • 8.1.4. Candidiasis
    • 8.1.5. Others

9. Antifungal Drugs Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 9.1.2. Oral
    • 9.1.3. Topical
    • 9.1.4. Injectable

10. Antifungal Drugs Market - By Infection Type

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Infection, 2023 & 2032 (%)
    • 10.1.2. Systemic antifungal infections
    • 10.1.3. Superficial antifungal infections

11. Antifungal Drugs Market - By Distribution Channel

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 11.1.2. Hospital pharmacies
    • 11.1.3. Retail pharmacies
    • 11.1.4. Others

12. Antifungal Drugs Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Antifungal Drugs Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Antifungal Drugs Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.10. Italy
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.10.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.10.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.10.6. Italy Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.3.10.7. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.11. United Kingdom
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.11.4. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.11.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.11.6. United Kingdom Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.3.11.7. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.12. France
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.12.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.12.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.12.6. France Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.3.12.7. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.13. Russia
      • 12.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.13.3. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Russia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.14. Netherlands
      • 12.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.14.3. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.14.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.14.5. Netherlands Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.3.14.6. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.16. Poland
      • 12.3.16.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.16.3. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Poland Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.17. Rest of Europe
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Rest of the Europe Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Antifungal Drugs Key Manufacturers in Asia Pacific
    • 12.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.4.5. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.4.7. Asia Pacific Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 12.4.8. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.9. India
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.9.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.9.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.9.6. India Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.4.9.7. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.10. China
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.10.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.10.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.10.6. China Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.4.10.7. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.14. Thailand
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Thailand Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.15. Indonesia
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Indonesia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.5. Latin America
    • 12.5.1. Overview
    • 12.5.2. Antifungal Drugs Key Manufacturers in Latin America
    • 12.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.5.5. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.5.7. Latin America Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 12.5.8. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Antifungal Drugs Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Antifungal Drugs Industry

  • 13.1. Competitive Dashboard
  • 13.2. Company Profiles
    • 13.2.1. Novartis AG
    • 13.2.2. Pfizer, Inc.
    • 13.2.3. Bayer AG
    • 13.2.4. Sanofi
    • 13.2.5. Merck & Co., Inc.
    • 13.2.6. GlaxoSmithKline plc
    • 13.2.7. Abbott
    • 13.2.8. Glenmark
    • 13.2.9. Enzon Pharmaceuticals, Inc.
    • 13.2.10. Astellas Pharma, Inc.
    • 13.2.11. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us